Tirzepatide vs SGLT2i in MASLD: Hepatology International | July 2026

Introduction:

Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data on long-term liver and cardiovascular outcomes have been limited. This large propensity-matched study compared these therapies in routine clinical practice.

Why was this study needed?

• Head-to-head real-world comparisons between tirzepatide and SGLT2 inhibitors are lacking.
• MASLD requires therapies that improve both hepatic and cardiometabolic outcomes.
• Long-term clinical outcome data beyond weight loss are limited.
• Real-world evidence is needed to complement randomized clinical trials.
• Better treatment selection could improve survival and reduce liver-related complications.

Results:

• Tirzepatide significantly reduced all-cause mortality, hospitalizations, major cardiovascular events, and major adverse liver outcomes compared with SGLT2 inhibitors.
• These clinical benefits were observed at 1 year and remained consistent through 3 years of follow-up.
• The findings suggest that tirzepatide may provide broader cardiometabolic and hepatic protection than SGLT2 inhibitors in patients with MASLD.

Clinical Impact:

This large real-world study supports tirzepatide as a highly effective therapeutic option for patients with MASLD and metabolic comorbidities. Beyond weight reduction and glycemic control, tirzepatide appears to improve both liver-related and cardiovascular outcomes, reinforcing its emerging role in the comprehensive management of MASLD.

Bottom Line:

Tirzepatide outperformed SGLT2 inhibitors across multiple clinically meaningful outcomes in patients with MASLD. These findings strengthen the growing evidence supporting tirzepatide as a preferred metabolic therapy for patients with fatty liver disease and associated cardiometabolic risk, while awaiting confirmation from prospective randomized trials.